Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lexaria BioscienceLEXX +11.60%41 Debt-to-Equity is 0.02 as of May. 2026, which is at its 10-year median of 0.02. GuruFocus rates LEXX with a GF Score™ of 41/100 and a GF Value™ of $5.38 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 970 Biotechnology companies, Lexaria Bioscience ranks better than 87.11% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lexaria Bioscience's Debt-to-Equity or its related term are showing as below:
LEXX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.17
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Lexaria Bioscience was 0.17. The lowest was 0.01. And the median was 0.02.
LEXX's Debt-to-Equity is ranked better than 87.11% of 970
companies
in the Biotechnology industry
Industry Median: 0.15
vs LEXX: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Lexaria Bioscience Debt-to-Equity Related Terms
Lexaria Bioscience Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LEXX vs CTXR, PTN, HIND: Debt-to-Equity Comparison
For the Biotechnology subindustry, Lexaria Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (LEXX) has a Debt-to-Equity of 0.02 as of May. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lexaria Bioscience and its competitors. This is near median its historical median of 0.02. Over the past decade, Lexaria Bioscience's Debt-to-Equity has ranged from 0.01 to 0.17. According to the industry distribution chart, Lexaria Bioscience ranks #125 out of 970 companies in the Biotechnology industry, placing it in the top 12.9%.
Is Lexaria Bioscience's Debt-to-Equity too high?
Lexaria Bioscience's current Debt-to-Equity of 0.02 is near median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.17. The Biotechnology industry median Debt-to-Equity is 0.15. Lexaria Bioscience's value of 0.02 is 86.7% below this industry median. Based on the distribution chart, Lexaria Bioscience ranks #125 out of 970 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lexaria Bioscience has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Debt-to-Equity compare to CTXR and PTN?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #125 out of 970 companies for Debt-to-Equity. This places Lexaria Bioscience in the top 13% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.15. Lexaria Bioscience's value of 0.02 is 86.7% below this benchmark. Historically, Lexaria Bioscience's own Debt-to-Equity has ranged from 0.01 to 0.17 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 0.15, Lexaria Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lexaria Bioscience's current Debt-to-Equity of 0.02 is 86.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lexaria Bioscience and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lexaria Bioscience's current Debt-to-Equity is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.38, compared to a current price of $8.84 — trading 64.3% above its estimated fair value. The current Debt-to-Equity is 0.02, which is near median its 10-year median of 0.02 and 86.7% below the Biotechnology industry median of 0.15. Lexaria Bioscience's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Debt-to-Equity is 0.02 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued.
The current stock price of $8.84 is trading 64.3% above its estimated GF Value™ of $5.38.
GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.
Key valuation signals for LEXX:
Debt-to-Equity: 0.02 (near median its 10-year median of 0.02)
GF Value™: $5.38 vs. price of $8.84 (64.3% above fair value)
Industry Position: 86.7% below the Biotechnology median (#125 of 970)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
41GF Score
Get the complete analysis for LEXX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
